Ally Bridge Group (Ny) LLC Janux Therapeutics, Inc. Transaction History
Ally Bridge Group (Ny) LLC
- $88.1 Million
- Q4 2024
A detailed history of Ally Bridge Group (Ny) LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Ally Bridge Group (Ny) LLC holds 90,292 shares of JANX stock, worth $2.83 Million. This represents 5.49% of its overall portfolio holdings.
Number of Shares
90,292
Previous 108,811
17.02%
Holding current value
$2.83 Million
Previous $4.94 Million
2.21%
% of portfolio
5.49%
Previous 3.51%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
229Shares Held
55.2MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$325 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$112 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$110 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$96 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$73.5 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.31B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...